NeurologyLive® Staff

Articles by NeurologyLive® Staff

FDA OKs Atlas Stent System, Wearables in Epilepsy Monitoring, and ASA Policy Statement on Stroke Care Systems

ByNeurologyLive® Staff

May 25th 2019

Neurology News Network for the week ending May 25, 2019.

New Guideline for Tourette Syndrome, Tic Disorders, FDA Approves sBLA for IncobotulinumtoxinA for Blepharospasm, Gaboxadol Shows Clinical Benefit in Angelman Syndrome

ByNeurologyLive® Staff

May 18th 2019

Neurology News Network for the week ending May 18, 2019.

Inebilizumab for NMOSD, New Acute Migraine Clinical Trial End Points, Eptinezumab's Pending BLA for Migraine Prevention

ByNeurologyLive® Staff

April 27th 2019

Neurology News Network for the week ending April 27, 2019.

Exome Panel Promising for Diagnosing Epilepsy, Pamrevlumab for Duchenne Muscular Dystrophy Receives Orphan Drug Designation, Riluzole NDA Accepted for ALS

ByNeurologyLive® Staff

April 20th 2019

Neurology News Network for the week of April 20, 2019.

Guidelines for Pediatric Migraine Clinical Trial Design Released, FDA Grants AMT-130 Fast Track Designation for Huntington Disease, ZX008 Receives RFL for Dravet Syndrome

ByNeurologyLive® Staff

April 13th 2019

Neurology News Network for the week of April 13, 2019.

Clardibine Approved for Relapsing, Secondary Progressive MS, Cervella Cranial Electrotherapy Approved for Insomnia, and Management of Stroke With Tandem Occlusion

ByNeurologyLive® Staff

April 6th 2019

Neurology News Network for the week of April 6, 2019.

Siponimod Approved for SPMS, AVP-786 Phase 3 Results for Treatment of Agitation in Alzheimer-Related Dementia, and Mobile Technology for Care of Parkinson Disease

ByNeurologyLive® Staff

March 30th 2019

Neurology News Network for the week of March 30, 2019.

Quality of Life is Predictive of DBS Outcomes in Early Parkinson, Lack of Approved Therapies for MS Symptoms, and Ubrogepant for Acute Treatment of Migraine in Adults

ByNeurologyLive® Staff

March 23rd 2019

Neurology News Network for the week of March 22, 2019.

Ned Sharpless as Acting FDA Commissioner, Temelimab in MS Extension Trial, and Post-Stroke Blood Panel Predicting Dementia

ByNeurologyLive® Staff

March 16th 2019

Neurology News Network for the week of March 16, 2019.

Gottlieb Resignation, Priority Review Granted to Galcanezumab for Prevention of Episodic Cluster Headache, Neurologists Treating MS Deviate From DMT Use

ByNeurologyLive® Staff

March 9th 2019

Neurology News Network for the week of March 9, 2019.

NDA Accepted for SRP-4053 for DMD, MPRI 2.0 Differentiates Parkinson and Progressive Supranuclear Palsy, and Young Donor Plasma Infusion Warning

ByNeurologyLive® Staff

February 23rd 2019

Neurology News Network for the week of February 23, 2019.

Patients with Parkinson at Greater Risk for Dementia After DBS Implant, a Novel ALS Diagnostic Index, Preliminary IGNITE-DMD Trial Findings

ByNeurologyLive® Staff

February 16th 2019

Neurology News Network for the week of February 14, 2019.

SPRINT-MIND Trial Results, Alemtuzumab and Rituximab Safe for MS, CAP-1002 for Duchenne Muscular Dystrophy

ByNeurologyLive® Staff

February 2nd 2019

Neurology News Network for the week of February 2, 2019.

Ocrelizumab Compared to Other DMTs, Effects of Lemborexant on Next-Day Driving, BHV-3241 Gets FDA OK for Clinical Trial

ByNeurologyLive® Staff

January 26th 2019

Neurology News Network for the week of January 26, 2019.

AHS Statement on CGRP Inhibitors, NDA Submitted for Lemborexant, Dabigatran Assessed in Alzheimer

ByNeurologyLive® Staff

January 19th 2019

Neurology News Network for the week of January 19, 2019.

Fumarate Bioequivalent for MS, Embrace Smartband Approval, Alzheimer Biomarkers Identified, Long-Term Perampanel Data

ByNeurologyLive® Staff

January 12th 2019

Neurology News Network for the week of January 12, 2019.

Solriamfetol PDUFA Date Pushed, Recognizing Parkinson Disease, Chronic Migraine Peer Exchange Program

ByNeurologyLive® Staff

January 5th 2019

Neurology News Network for the week of January 5, 2019.

Oxtellar XR Approved as Monotherapy, Pregnancy Safety Data for Betaseron, and Biologic Brain Changes in Migraine

ByNeurologyLive® Staff

December 22nd 2018

Neurology News Network for the week of December 22, 2018.

Zilucoplan for Mysathenia Gravis, AXS-05 for Agitation in Alzheimer, and Chronic Migraine Management

ByNeurologyLive® Staff

December 15th 2018

Neurology News Network for the week of December 15, 2018.

Fingolimod Issued a Safety Warning, an NDA for BHV-0223 for ALS, and Lifestyle Modifications for Patients with Migraine

ByNeurologyLive® Staff

December 8th 2018

Neurology News Network for the week of December 1, 2018.

Galcanezumab for Cluster Headache, a Link Between Carotid Webs and Stroke, Managing Migraine Patient Relationships

ByNeurologyLive® Staff

November 24th 2018

Neurology News Network for the week of November 24, 2018.

An FDA Warning Letter, the Amyloid Hypothesis and Alzheimer Disease, Adverse Events with Triptan Use

ByNeurologyLive® Staff

November 17th 2018

Neurology News Network for the week of November 17, 2018.

Confounding Outcomes in Alzheimer, AFib and Dementia Risk, Cognitive Issues in Epilepsy, and MRI Imaging

ByNeurologyLive® Staff

November 10th 2018

Neurology News Network for the week of November 10, 2018.

Sodium Oxybate Approved, ANAVEX 2-73 Shows Positive Results, Ubrogepant for Acute Migraine Care, and Stroke Risk with Migraine

ByNeurologyLive® Staff

November 3rd 2018

Neurology News Network for the week of November 3, 2018.

Novel Deep Brain Stimulation System, ITI-214 Safe for Parkinson Disease, Elizabeth Ross on the Field's Progress

ByNeurologyLive® Staff

October 27th 2018

Neurology News Network for the week of Oct. 27, 2018.

New Alzheimer Association AUC, Patisiran Findings from AANEM, Evobrutinib findings from ECTRIMS

ByNeurologyLive® Staff

October 20th 2018

Neurology News Network for the week of October 20, 2018.

Siponimod NDA Accepted, New Appropriate Use Criteria for Alzheimer Disease Diagnosis, Disease-Modifying Therapy

ByNeurologyLive® Staff

October 13th 2018

Neurology News Network for the week of Oct. 12, 2018.

Never Events Common in Parkinson, Donepezil Fails to Prevent Psychosis, Helping Patients Live Well

ByNeurologyLive® Staff

October 6th 2018

Neurology News Network for the week of October 6, 2018.

Galcanezumab Approved, Pimavanserin Safety Confirmed, Treating Augmentation in RLS, Genetics in Alzheimer

ByNeurologyLive® Staff

September 29th 2018

Neurology News Network for the week of September 28, 2018.

FDA Approves Fremanezumab, Behavioral Activation Therapy for MCI, Choosing DMTs for MS

ByNeurologyLive® Staff

September 22nd 2018

Neurology News Network for the week of September 22, 2018.

NeurologyLive® Staff

Articles by NeurologyLive® Staff

FDA OKs Atlas Stent System, Wearables in Epilepsy Monitoring, and ASA Policy Statement on Stroke Care Systems

New Guideline for Tourette Syndrome, Tic Disorders, FDA Approves sBLA for IncobotulinumtoxinA for Blepharospasm, Gaboxadol Shows Clinical Benefit in Angelman Syndrome

Inebilizumab for NMOSD, New Acute Migraine Clinical Trial End Points, Eptinezumab's Pending BLA for Migraine Prevention

Exome Panel Promising for Diagnosing Epilepsy, Pamrevlumab for Duchenne Muscular Dystrophy Receives Orphan Drug Designation, Riluzole NDA Accepted for ALS

Guidelines for Pediatric Migraine Clinical Trial Design Released, FDA Grants AMT-130 Fast Track Designation for Huntington Disease, ZX008 Receives RFL for Dravet Syndrome

Clardibine Approved for Relapsing, Secondary Progressive MS, Cervella Cranial Electrotherapy Approved for Insomnia, and Management of Stroke With Tandem Occlusion

Siponimod Approved for SPMS, AVP-786 Phase 3 Results for Treatment of Agitation in Alzheimer-Related Dementia, and Mobile Technology for Care of Parkinson Disease

Quality of Life is Predictive of DBS Outcomes in Early Parkinson, Lack of Approved Therapies for MS Symptoms, and Ubrogepant for Acute Treatment of Migraine in Adults

Ned Sharpless as Acting FDA Commissioner, Temelimab in MS Extension Trial, and Post-Stroke Blood Panel Predicting Dementia

Gottlieb Resignation, Priority Review Granted to Galcanezumab for Prevention of Episodic Cluster Headache, Neurologists Treating MS Deviate From DMT Use

NDA Accepted for SRP-4053 for DMD, MPRI 2.0 Differentiates Parkinson and Progressive Supranuclear Palsy, and Young Donor Plasma Infusion Warning

Patients with Parkinson at Greater Risk for Dementia After DBS Implant, a Novel ALS Diagnostic Index, Preliminary IGNITE-DMD Trial Findings

SPRINT-MIND Trial Results, Alemtuzumab and Rituximab Safe for MS, CAP-1002 for Duchenne Muscular Dystrophy

Ocrelizumab Compared to Other DMTs, Effects of Lemborexant on Next-Day Driving, BHV-3241 Gets FDA OK for Clinical Trial

AHS Statement on CGRP Inhibitors, NDA Submitted for Lemborexant, Dabigatran Assessed in Alzheimer

Fumarate Bioequivalent for MS, Embrace Smartband Approval, Alzheimer Biomarkers Identified, Long-Term Perampanel Data

Solriamfetol PDUFA Date Pushed, Recognizing Parkinson Disease, Chronic Migraine Peer Exchange Program

Oxtellar XR Approved as Monotherapy, Pregnancy Safety Data for Betaseron, and Biologic Brain Changes in Migraine

Zilucoplan for Mysathenia Gravis, AXS-05 for Agitation in Alzheimer, and Chronic Migraine Management

Fingolimod Issued a Safety Warning, an NDA for BHV-0223 for ALS, and Lifestyle Modifications for Patients with Migraine

Galcanezumab for Cluster Headache, a Link Between Carotid Webs and Stroke, Managing Migraine Patient Relationships

An FDA Warning Letter, the Amyloid Hypothesis and Alzheimer Disease, Adverse Events with Triptan Use

Confounding Outcomes in Alzheimer, AFib and Dementia Risk, Cognitive Issues in Epilepsy, and MRI Imaging

Sodium Oxybate Approved, ANAVEX 2-73 Shows Positive Results, Ubrogepant for Acute Migraine Care, and Stroke Risk with Migraine

Novel Deep Brain Stimulation System, ITI-214 Safe for Parkinson Disease, Elizabeth Ross on the Field's Progress

New Alzheimer Association AUC, Patisiran Findings from AANEM, Evobrutinib findings from ECTRIMS

Siponimod NDA Accepted, New Appropriate Use Criteria for Alzheimer Disease Diagnosis, Disease-Modifying Therapy

Never Events Common in Parkinson, Donepezil Fails to Prevent Psychosis, Helping Patients Live Well

Galcanezumab Approved, Pimavanserin Safety Confirmed, Treating Augmentation in RLS, Genetics in Alzheimer

FDA Approves Fremanezumab, Behavioral Activation Therapy for MCI, Choosing DMTs for MS

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

How Multiple Sclerosis Affects Men

Understanding Ocrelizumab’s Impact on Advanced Progressive MS: Insights From Dr. Gavin Giovannoni

Trofinetide Leads to Real-World Improvements in Rett Syndrome Symptoms, LOTUS Study Finds

Key Highlights from the 2025 American Neurological Association Annual Meeting

This Week on NeurologyLive® — October 13, 2025